OECD Home › Science and technology › By Country › Japan
This book draws on work on green innovation across several parts of the OECD to show how it can drive sustainable growth and job creation. It explores policy actions for the deployment of new technologies and innovations as they emerge.
This book examines dynamics between demand and innovation and provides insights into the rationale and scope for public policies. Drawing on country experience and case studies, it illustrates good practices for designing, implementing and evaluating demand-side innovation policies.
The OECD/NEA will co-organise a G8-G20 meeting on nuclear energy safety issues 7-8 June, as part of international efforts to learn from the accident at Japan’s Fukushima Daiichi nuclear power plant and help prevent similar disasters in the future.
The OECD STI Outlook provides profiles of the science and innovation performance of each OECD country and certain non-members in relation to their national context and policy issues. The graphs enable countries to see some of their relative strengths and weaknesses compared to other countries.&l
What impact has the crisis had on innovation and spending on research and development? How can innovation help to solve environmental and social threats? The OECD Science, Technology and Industry Scoreboard 2009 provides the data and analysis to answer these questions.
This conference will consider innovation in the software sector from business and economic perspectives, taking into account the factors that drive innovation, including key framework conditions.
OECD member countries, as well as some non-member economies and other stakeholders, are pooling expertise and funding to test the human health and environmental safety effects of a number of nanomaterials.
This symposium will be held on 23rd April 2007 in Tokyo, Japan. A two-day OECD WPMN meeting - OECD Workshop on the Sponsorship Programme for the Testing of Manufactured Nanomaterials - will follow this event to discuss the sponsorship programme for the testing of manufactured nanomaterials.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.